throbber
USOO892.1348B2
`
`(12) United States Patent
`Belanoff
`
`(10) Patent No.:
`(45) Date of Patent:
`
`US 8,921,348 B2
`Dec. 30, 2014
`
`(54) OPTIMIZING MIFEPRISTONE LEVELS IN
`PLASMA SERUM OF PATIENTS SUFFERING
`FROMMENTAL DISORDERS TREATABLE
`WITH GLUCOCORTICOD RECEPTOR
`ANTAGONSTS
`(71) Applicant: Corcept Therapeutics, Menlo Park, CA
`US
`(US)
`(72) Inventor: Joseph K. Belanoff, Woodside, CA (US)
`
`(52) U.S. Cl.
`CPC ................ G0IN33/49 (2013.01); A61 K3I/56
`(2013.01); A61 K3I/575 (2013.01)
`USPC .......................................................... S14/178
`(58) Field of Classification Search
`USPC .......................................................... 514/178
`See application file for complete search history.
`References Cited
`U.S. PATENT DOCUMENTS
`
`(56)
`
`(73) Assignee: Corcept Therapeutics, Inc., Menlo
`Park, CA (US)
`
`(65)
`
`(*) Notice:
`
`Subject to any disclaimer, the term of this
`patent is extended or adjusted under 35
`U.S.C. 154(b) by 0 days
`M
`YW-
`(21) Appl. No.: 14/065,792
`(22) Filed:
`Oct. 29, 2013
`O
`O
`Prior Publication Data
`US 2014/O162993 A1
`Jun. 12, 2014
`un. IZ,
`Related U.S. Application Data
`(63) Continuation of application No. 12/199,114, filed on
`Aug. 27, 2008, now Pat. No. 8 598 149 s u u is
`2. 4
`s
`vs. V3 - - V -
`I -
`(60) Provisional application No. 60/969,027, filed on Aug.
`30, 2007.
`
`(51) Int. Cl.
`A6 IK3I/56
`GOIN 33/49
`A 6LX3/575
`
`(2006.01)
`(2006.01)
`(2006.01)
`
`6,964,953 B2 11/2005 Belanoff
`- w
`O
`OTHER PUBLICATIONS
`
`Medical Encyclopedia of Medline (http:// http://www.nlm.nih.gov/
`medlineplus/ency/article/003430.htm), 4 pages, Oct. 2005.
`Sarkar, “Mifepristone: bioavailability, pharmacokinetics and use
`effectiveness.” European Journal of Obstetrics and Gynecology and
`Reproductive Biology, vol. 101, pp. 113-120 (2002).
`Primary Examiner — San-Ming Hui
`(74) Attorney, Agent, or Firm — Kilpatrick Townsend &
`Stockton LLP
`
`ABSTRACT
`(57)
`The present invention provides a method for optimizing lev
`els of mifepristone in a patient Suffering from a mental dis
`order amenable to treatment by mifepristone. The method
`comprises the steps of treating the patient with seven or more
`daily doses of mifepristone over a period of seven or more
`days; testing the serum levels of the patient to determine
`whether the blood levels of mifepristone are greater than 1300
`ng/mL, and adjusting the daily dose of the patient to achieve
`mifepristone blood levels greater than 1300 ng/mL.
`
`7 Claims, 6 Drawing Sheets
`
`-
`
`:
`
`:
`
`BPRS PSS-Days 7 and 56 Response
`40 m-
`
`
`
`35
`
`30 -
`% of patients
`-
`is
`save at
`25
`338.3%
`fei:
`from baseline 20 -
`ir 333, 88
`scores a
`days 7 and 56 5 l
`10
`5
`O --
`
`Corux
`3
`
`Pace
`at 3
`
`1
`
`TEVA1019
`
`

`

`U.S. Patent
`
`US 8,921,348 B2
`
`
`
`
`
`
`
`asuodsæ8 99 pue 1 sÁed- ssd sejag
`
`2
`
`

`

`
`
`
`
`ºsuodsæ8 9g pue 1 sÁed – ssd sædag
`
`U.S. Patent
`
`Dec. 30, 2014
`
`Sheet 2 of 6
`
`?????????????????????%8%|
`
`3
`
`

`

`U.S. Patent
`
`Dec. 30, 2014
`
`Sheet 3 of 6
`
`US 8,921,348 B2
`
`
`
`s
`
`
`
`ºsuodsæ8 99 pue 1 sÁed – ssa sada
`
`
`
`4
`
`

`

`U.S. Patent
`
`Dec. 30, 2014
`
`Sheet 4 of 6
`
`US 8,921,348 B2
`
`
`
`%)?
`
`
`
`99 p??º 1sÁed3esesuodsax~ 88e3 S8d8
`
`
`
`
`
`04’ zd
`
`· §9
`
`04.
`
`-------
`
`---are--
`
`
`
`$$$$ $&##### ###
`
`5
`
`

`

`U.S. Patent
`
`Dec. 30, 2014
`
`Sheet 5 of 6
`
`US 8,921,348 B2
`
`
`
`
`
`ºsuodsæ8 99 pue 1 sÁed – ssa saag
`
`ºg 3.88333
`
`6
`
`

`

`US 8,921,348 B2
`
`U.S. Patent
`
`
`
`
`
`asuodsæ8 99 pue 1 sÁed-- ssd sada
`
`7
`
`

`

`US 8,921,348 B2
`
`1.
`OPTIMIZING MIFEPRSTONE LEVELS IN
`PLASMA SERUM OF PATIENTS SUFFERING
`FROMMENTAL DISORDERS TREATABLE
`WITH GLUCOCORTICOD RECEPTOR
`ANTAGONSTS
`
`CROSS-REFERENCES TO RELATED
`APPLICATIONS
`
`This application claims priority to U.S. Provisional Appli
`cation No. 60/969,027, filed Aug. 30, 2007, the disclosure of
`which is incorporated herein in its entirety.
`
`STATEMENT AS TO RIGHTS TO INVENTIONS
`MADE UNDER FEDERALLY SPONSORED
`RESEARCH AND DEVELOPMENT
`
`Not Applicable
`
`REFERENCE TO A “SEQUENCE LISTING. A
`TABLE, ORACOMPUTER PROGRAM LISTING
`APPENDIX SUBMITTED ON A COMPACT DISK
`
`Not Applicable
`
`BACKGROUND OF THE INVENTION
`
`It has been Surprisingly discovered that administration of
`the same dose of mifepristone can produce widely varying
`blood serum levels in different patients. The varied blood
`serum levels can result in some patients not receiving an
`efficacious dose of mifepristone. For the same dose of mife
`pristone, the blood serum levels can differ by as much as
`800% from one patient to another. Thus, a method for ensur
`ing that the blood serum levels of mifepristone remain in an
`efficacious and safe range is needed.
`
`BRIEF SUMMARY OF THE INVENTION
`
`10
`
`15
`
`25
`
`30
`
`35
`
`2
`In a second embodiment, the present invention provides a
`kit for treating a mental disorder amenable to treatment by
`mifepristone, the kit comprising: seven daily doses of mife
`pristone; and a plasma sampling collection device Suitable for
`detecting mifepristone serum levels.
`
`BRIEF DESCRIPTION OF THE DRAWINGS
`
`FIG. 1 shows a comparison of patients receiving CorluX vs.
`placebo on primary endpoint (OC) for all studies. Of the
`patients receiving Corlux, 35% of the patients showed at least
`a 50% reduction from baseline in BPRS PSS scores at days 7
`and 56, versus 26% of patients receiving the placebo.
`FIG. 2 shows a comparison of patients with plasma
`levels >1357 ng/mL vs.<1357 ng/mL vs. placebo (OC) for all
`studies. Of the patients having plasma levels of greater than
`1357 ng/mL, 40% of the patients showed at least a 50%
`reduction from baseline in BPRSPSS scores at days 7 and 56,
`versus 27% of patients having plasma levels of less than 1357
`ng/mL and 26% of patients receiving the placebo.
`FIG. 3 shows a comparison of patients with plasma
`levels >1661 ng/ml vs. placebo (OC) for all studies. Of the
`patients having plasma levels of greater than 1661 ng/mL,
`44% of the patients showed at least a 50% reduction from
`baseline in BPRSPSS scores at days 7 and 56, versus 29% of
`patients having plasma levels of less than 1661 ng/mL and
`26% of patients receiving the placebo.
`FIG. 4 shows a comparison of patients receiving CorluX vs.
`placebo on primary endpoint (OC) for the 1200 mg group. Of
`the patients receiving the 1200 mg dose of Corlux, 47% of the
`patients showed at least a 50% reduction from baseline in
`BPRS PSS scores at days 7 and 56, versus 34% of patients
`receiving the placebo.
`FIG. 5 shows a comparison of patients with plasma
`levels >1357 ng/ml vs. placebo (OC) for the 1200 mg group.
`Of the patients in the 1200 mg group having plasma levels of
`greater than 1357 ng/mL, 54% of the patients showed at least
`a 50% reduction from baseline in BPRS PSS scores at days 7
`and 56, versus 31% of patients having plasma levels of less
`than 1357 ng/mL and 34% of patients receiving the placebo.
`FIG. 6 shows a comparison of patients with plasma
`levels >1661 ng/ml vs. placebo (OC) for the 1200 mg group.
`Of the patients in the 1200 mg group having plasma levels of
`greater than 1661 ng/mL, 58% of the patients showed at least
`a 50% reduction from baseline in BPRS PSS scores at days 7
`and 56, versus 39% of patients having plasma levels of less
`than 1661 ng/mL and 34% of patients receiving the placebo.
`
`DETAILED DESCRIPTION OF THE INVENTION
`
`40
`
`45
`
`In one embodiment, the present invention provides a
`method for optimizing levels of mifepristone in a patient
`suffering from a mental disorder amenable to treatment by
`mifepristone, the method comprising: treating the patient
`with seven or more daily doses of mifepristone over a period
`of seven or more days; testing the serum levels of the patient
`to determine whether the blood levels of mifepristone are
`greater than 1300 ng/mL, and adjusting the daily dose of the
`patient to achieve mifepristone blood levels greater than 1300
`ng/mL.
`In some embodiments, the mental disorder is a member
`selected from the group consisting of a stress disorder,
`delirium, mild cognitive impairment (MCI), dementia, psy
`chosis and psychotic major depression. In other embodi
`ments, the stress disorder is a member selected from the group
`consisting of Acute Stress Disorder, Post-Traumatic Stress
`Disorder and Brief Psychotic Disorder with Marked
`Stressor(s).
`In another embodiment, each of the seven or more daily
`doses of mifepristone are administered orally. In other
`embodiments, the patient is treated with 28 or more daily
`doses over a period of 28 or more days.
`In a further embodiment, the testing is performed by a
`plasma sampling collection device Suitable for detecting
`mifepristone serum levels.
`In other embodiments, the adjusting step comprises
`increasing the daily dose of the patient to achieve mifepris
`tone blood levels greater than 1300 ng/mL.
`
`50
`
`55
`
`60
`
`65
`
`I. Introduction
`Administration of the same dose of mifepristone can pro
`duce widely varying mifepristone blood serum levels in dif
`ferent patients. For the same dose, the blood serum levels can
`differ by as much as 800% from one patient to another. For
`those patients with lower blood serum levels, the effective
`ness of mifepristone treatment can Suffer significantly. The
`present invention provides a method for optimizing the blood
`serum levels of mifepristone so that the blood serum levels
`remain in an efficacious range and the patient receives the
`necessary treatment.
`The method of the present invention optimizes blood
`serum levels of mifepristone in a patient Suffering from a
`mental disorder amenable to treatment by mifepristone by
`first treating the patient with mifepristone. The treatment can
`be for any appropriate period of time. Such as seven or more
`daily doses over a period of seven or more days. Following
`
`8
`
`

`

`US 8,921,348 B2
`
`3
`treatment for an appropriate period of time, the serum levels
`of the patient are tested to determine whether the blood levels
`of mifepristone are greater than 1300 ng/mL. The daily dose
`of the patient is then adjusted in order to achieve mifepristone
`blood levels of greater than 1300 ng/mL.
`II. Definitions
`The term “amenable to treatment by mifepristone' refers to
`a condition that is known to be treated by glucocorticoid
`antagonists Such as mifepristone. Conditions such as mental
`disorders (discussed below) are amenable to treatment by
`mifepristone.
`The term “mental disorder” refers to disorders of the mind
`that can be treated with a glucocorticoid antagonist Such as
`mifepristone. Mental disorders amenable to treatment by the
`methods of the present invention include, but are not limited
`to, a stress disorder, delirium, mild cognitive impairment
`(MCI), dementia, psychosis and psychotic major depression.
`The term “stress disorder” refers to a psychiatric condition
`precipitated by exposure to a traumatic or stressful event.
`Stress disorders include Acute Stress Disorder, Post-Trau
`matic Stress Disorder, and Brief Psychotic Disorder with
`Marked Stressor(s).
`The term "Acute Stress Disorder refers to a psychiatric
`condition in its broadest sense, as defined in American Psy
`chiatric Association: Diagnostic and Statistical Manual of
`Mental Disorders, Fourth Edition, Text Revision, Washing
`ton, D.C., 2000 (“DSM-IV-TR). The DSM-IV-TR defines
`Acute Stress Disorder as characterized by anxiety, disso
`ciative, and other symptoms occurring within 1 month after
`exposure to an extreme traumatic stressor. The DSM-IV-TR
`sets forth a generally accepted Standard for diagnosing and
`categorizing Acute Stress Disorder.
`The term “Brief Psychotic Disorder with Marked
`Stressor(s) refers to a psychiatric condition in its broadest
`sense, as defined in DSM-IV-TR. The DSM-IV-TR defines
`“Brief Psychotic Disorder with Marked Stressor(s)' as a sud
`den but briefonset of psychotic symptoms developing shortly
`after and apparently in response to one or more stressful
`events. The DSM-IV-TR sets forth a generally accepted stan
`dard for diagnosing and categorizing Brief Psychotic Disor
`der with Marked Stressor(s).
`The term “delirium” refers to a psychiatric condition in its
`broadest sense, as defined in American Psychiatric Associa
`tion: Diagnostic and Statistical Manual of Mental Disorders,
`Fourth Edition, Text Revision, Washington, D.C., 2000
`(“DSM-IV-TR). The DSM-IV-TR defines “delirium” as a
`disturbance of consciousness, developing over a short period
`of time, accompanied by a change in cognition that cannot be
`better accounted for by a preexisting or evolving dementia.
`The DSM-IV-TR sets forth a generally accepted standard for
`diagnosing and categorizing delirium.
`The term “dementia' refers to a psychiatric condition in its
`broadest sense, as defined in American Psychiatric Associa
`tion: Diagnostic and Statistical Manual of Mental Disorders,
`Fourth Edition, Washington, D.C., 1994 (“DSM-IV). The
`DSM-IV defines “dementia” as characterized by multiple
`cognitive deficits that include impairments in memory and
`lists various dementias according to presumed etiology. The
`DSM-IV sets forth a generally accepted standard for such
`diagnosing, categorizing and treating of dementia and asso
`ciated psychiatric disorders.
`The term “mild cognitive impairment (MCI) refers to a
`category of memory and cognitive impairment that is typi
`cally characterized by a clinical dementia rating (CDR) of 0.5
`(see, e.g., Hughes et al., Brit. J. Psychiat. 140:566-572, 1982)
`and further characterized by memory impairment, but not
`impaired function in other cognitive domains. Memory
`
`40
`
`45
`
`4
`impairment is preferably measured using tests Such as a
`“paragraph test'. A patient diagnosed with MCI often exhib
`its impaired delayed recall performance. MCI is typically
`associated with aging and generally occurs in patients who
`are 45 years of age or older.
`The term “mifepristone” refers to a family of compositions
`also referred to as RU486, or RU38.486, or 17-beta-hydroxy
`11-beta-(4-dimethyl-aminophenyl)-17-alpha-(1-propynyl)-
`estra-4,9-dien-3-one), or 11-beta-(4-dimethylaminophenyl)-
`17-beta-hydroxy-17-alpha-(1-propynyl)-estra-4,9-dien-3-
`one), or analogs thereof, which bind to the glucocorticoid
`receptor (GR), typically with high affinity, and inhibit the
`biological effects initiated/mediated by the binding of any
`cortisol or cortisol analogue to a GR receptor (as discussed
`within). Salts, hydrates and prodrugs of mifepristone are all
`within the scope of the present invention.
`The term “Post-Traumatic Stress Disorder refers to a psy
`chiatric condition in its broadest sense, as defined in DSM
`IV-TR. The DSM-IV-TR defines “Post-Traumatic Stress Dis
`order as characterized by persistent re-experiencing of an
`extreme traumatic event. The DSM-IV-TR sets forth a gen
`erally accepted Standard for diagnosing and categorizing
`Post-Traumatic Stress Disorder.
`The term “psychotic” as used herein refers to a psychiatric
`condition in its broadest sense, as defined in the DSM-IV
`(Kaplan, ed. (1995) supra) and described below. The term
`“psychotic” has historically received a number of different
`definitions, ranging from narrow to broadly described. A
`psychotic condition can include delusions or prominent hal
`lucinations, including prominent hallucinations that the indi
`vidual realizes are hallucinatory experiences, and those with
`hallucinations occurring in the absence of insight into their
`pathological nature. Finally, the term includes a psychotic
`condition characterized by a loss of ego boundaries or a gross
`impairment in reality testing. Unlike this definition, which is
`broad and based primarily on symptoms, characterization of
`psychosis in earlier classifications (e.g., DSM-II and ICD-9)
`were more inclusive and focused on the severity of functional
`impairment (so that a mental disorder was termed “psy
`chotic' if it resulted in “impairment” that grossly interferes
`with the capacity to meet ordinary demands of life). Different
`disorders which have a psychotic component comprise dif
`ferent aspects of this definition of “psychotic. For example,
`in schizophreniform disorder, schizoaffective disorder and
`brief psychotic disorder, the term "psychotic” refers to delu
`sions, any prominent hallucinations, disorganized speech, or
`disorganized or catatonic behavior. In psychotic disorder due
`to a general medical condition and in Substance-induced psy
`chotic disorder, “psychotic’ refers to delusions or only those
`hallucinations that are not accompanied by insight. Finally, in
`delusional disorder and shared psychotic disorder, “psy
`chotic' is equivalent to “delusional' (see DSM-IV. Supra,
`page 273).
`Objective tests can be also be used to determine whetheran
`individual is psychotic and to measure and assess the Success
`of a particular treatment schedule or regimen. For example,
`measuring changes in cognitive ability aids in the diagnosis
`and treatment assessment of the psychotic patient. Any test
`known in the art can be used, such as the so-called “Wallach
`Test, which assesses recognition memory (see below,
`Wallach (1980) J. Gerontol. 35:371-375). Another example
`of an objective text which can be used to determine whether
`an individual is psychotic and to measure efficacy of an anti
`psychotic treatment is the Stroop Color and Word Test
`(“Stroop Test”) (see Golden, C. J., Cat. No. 3015OM, In A
`Manual for Clinical and Experimental Uses, Stoelting, Wood
`Dale, Ill.) The Stroop Test is an objective neuropsychiatric
`
`10
`
`15
`
`25
`
`30
`
`35
`
`50
`
`55
`
`60
`
`65
`
`9
`
`

`

`US 8,921,348 B2
`
`10
`
`15
`
`30
`
`35
`
`40
`
`5
`test that can differentiate between individuals with psychosis
`and those without, and is described in detail below.
`The term "psychosis' refers to a psychiatric symptom,
`condition or syndrome in its broadest sense, as defined in the
`DSM-IV (Kaplan, ed. (1995) supra), comprising a “psy
`chotic' component, as broadly defined above. The term psy
`chosis can refer to a symptom associated with a general
`medical condition, a disease state or other condition, such as
`a side effect of drug abuse (a Substance-induced disorder) or
`as a side effect of a medication. Alternatively, the term psy
`chosis can refer to a condition or syndrome not associated
`with any disease state, medical condition, drug intake or the
`like.
`Psychosis is typically defined as a mental disorder or con
`dition causing gross distortion or disorganization of a per
`son’s mental capacity, affective response, and capacity to
`recognize reality, communicate, and relate to others to the
`degree of interfering with his capacity to cope with the ordi
`nary demands of everyday life.
`The term “psychotic major depression, also referred to as
`“psychotic depression' (Schatzberg (1992) Am. J. Psychiatry
`149:733-745), “psychotic (delusional) depression” (Ibid.),
`"delusional depression” (Glassman (1981) supra) and,
`“major depression with psychotic features” (see the DSM
`III-R), refers to a distinct psychiatric disorder which includes
`25
`both depressive and psychotic features. Individuals manifest
`ing both depression and psychosis, i.e. psychotic depression,
`are herein referred to as “psychotic depressives.” It has been
`long-recognized in the art as a distinct syndrome, as
`described, for example, by Schatzberg (1992) supra. Illustra
`tive of this distinctness are studies which have found signifi
`cant differences between patients with psychotic and nonpsy
`chotic depression in glucocorticoid activity, dopamine-beta
`hydroxylase activity, levels of dopamine and serotonin
`metabolites, sleep measures and Ventricle to brain ratios.
`Psychotic depressives respond very differently to treatment
`compared to individuals with other forms of depression, such
`as “non-psychotic major depression. Psychotic depressives
`have a low placebo response rate and respond poorly to anti
`depressant therapy alone (without concurrent anti-psychotic
`treatment). Psychotic depressives are markedly unresponsive
`to tricyclic (anti-depressive) drug therapy (Glassman, et al.
`(1975) supra). While psychotic depressives can respond to
`electroconvulsive therapy (ECT), their response time is rela
`tively slow and the ECT has a high level of related morbidity.
`Clinical manifestations and diagnostic parameters of “psy
`chotic major depression' is described in detail in the DSM-IV
`(Kaplan, ed. (1995) supra). Thus, due to its unique patho
`physiology, high rate of morbidity and response to treatment,
`there is great practical need to differentially diagnose and
`specifically treat psychotic major depression as compared to
`non-psychotic depression.
`The term “optimizing” refers to the process of testing mife
`pristone blood levels and adjusting the dosage of mifepristone
`administered to the patient in need in order to achieve mife
`pristone blood levels above 1300 ng/mL.
`The terms “treat”, “treating and “treatment collectively
`refer to any indicia of success in the treatment oramelioration
`of an injury, pathology or condition, including any objective
`or subjective parameter Such as abatement; remission; dimin
`ishing of symptoms or making the injury, pathology or con
`dition more tolerable to the patient; slowing in the rate of
`degeneration or decline; making the final point of degenera
`tion less debilitating; improving a patient's physical or men
`tal well-being; or, in Some situations, preventing the onset of
`65
`dementia. The treatment or amelioration of symptoms can be
`based on objective or Subjective parameters; including the
`
`55
`
`45
`
`50
`
`60
`
`6
`results of a physical examination, neuropsychiatric exams,
`and/or a psychiatric evaluation.
`The term “testing refers to determining the mifepristone
`blood levels in a patient. The testing can be performed by any
`Suitable instrument, Such as a plasma sampling collection
`device capable of detecting mifepristone serum levels.
`III. Method for Optimizing Mifepristone Levels
`Administration of the same dose of mifepristone to differ
`ent patients can produce widely varying blood serum levels,
`varying by up to 800% from one patient to another, resulting
`in decreased efficacy. The present invention provides a
`method for optimizing the blood serum levels of mifepristone
`so that the blood serum levels remain in an efficacious range
`and the patient receives the necessary treatment.
`A. Patients in Need
`Patients amenable to treatment with mifepristone accord
`ing to the method of the present invention suffer from any
`mental disorder. Exemplary mental disorders include, but are
`not limited to, a stress disorder, delirium, mild cognitive
`impairment (MCI), dementia, psychosis and psychotic major
`depression.
`Stress disorders treatable by the methods of the present
`invention include, but are not limited to, Acute Stress Disor
`der (ASD), Post-Traumatic Stress Disorder and Brief Psy
`chotic Disorder with Marked Stressor(s).
`Acute Stress Disorder (ASD) is characterized by a constel
`lation of symptoms, lasting at least two days, that appearand
`resolve within one month of exposure to an extreme traumatic
`stressor. If symptoms appear or persist beyond one month
`after exposure to the traumatic stressor, the patient may be
`considered to suffer from Post-Traumatic Stress Disorder
`rather than ASD. ASD is a common precursor to Post-Trau
`matic Stress Disorder, and up to 80% of trauma survivors
`initially suffering from ASD will meet the diagnostic criteria
`for Post-Traumatic Stress Disorder six months later (see
`Brewin et al., Am J Psychiatry 156:360-6, 1999).
`Patients develop ASD following exposure to an extreme
`traumatic stressor (DSM-IV-TR Criterion A). A person must
`respond to the stressor with intense fear, helplessness, or
`horror to be diagnosed with ASD. ASD may develop from
`direct experience of traumatic events, including violent
`crimes, physical trauma, combat, diagnosis with a life-threat
`ening illness, and natural or manmade disasters. Patients may
`also develop ASD from witnessing or learning about trau
`matic events that happen to others, especially family mem
`bers or close friends. Unexpected exposure to death, dead
`bodies, or body parts may also induce ASD.
`A diagnosis of ASD requires that the person meet several
`other symptomatic criteria. The person must experience three
`or more dissociative symptoms in connection with the trau
`matic stressor (Criterion B). Dissociative symptoms include a
`Subjective sense of numbing or detachment, a reduction in
`awareness of Surroundings, derealization, depersonalization,
`and dissociative amnesia. Furthermore, ASD requires that the
`victim persistently re-experience the traumatic event, though
`recurrent images, thoughts, dreams, illusions, flashbacks,
`sense of reliving the event, or distress upon exposure to
`reminders of the event (Criterion C). The person must display
`marked avoidance of stimuli that arouse recollection of the
`trauma (Criterion D) and marked symptoms of anxiety or
`increased arousal (Criterion E). Finally, in addition to the time
`requirements described above, a diagnosis of ASD requires
`that the disturbance cause significant distress; or life impair
`ment, and not be due to another psychiatric or physiological
`condition (Criteria F-H).
`Like Acute Stress Disorder, Post-Traumatic Stress Disor
`der (PTSD) emerges following exposure to an extreme trau
`
`10
`
`

`

`US 8,921,348 B2
`
`10
`
`15
`
`25
`
`30
`
`7
`matic stressor, and is characterized by persistent reexperienc
`ing of the traumatic event, avoidance of Stimuli associated
`with the trauma, and anxiety or increased arousal. The types
`of traumatic stressors giving rise to PTSD, and the manifes
`tations of PTSD symptoms, are identical to those described
`above for ASD, but for three differences. First, the dissocia
`tive symptoms required for a diagnosis of ASD are not
`required for a diagnosis of PTSD, although dissociative
`symptoms may commonly be seen in PTSD patients. Sec
`ondly, PTSD need not arise within one month of exposure to
`the traumatic stressor, and may emerge months or years after
`the traumatic event. Thirdly, in contrast to the one month
`maximum duration of symptoms required for a diagnosis of
`ASD, symptoms must persist for at least one month in order
`for a diagnosis of PTSD to be made.
`A Brief Psychotic Disorder is a short-term (between one
`day and one month) disturbance involving the Sudden onset of
`at least one psychotic symptom, such as delusions, halluci
`nations, disorganized speech, or grossly disorganized or cata
`tonic behavior. Brief Psychotic Disorders exclude those
`induced by a general medical condition. If psychotic symp
`toms develop shortly after, and apparently in response to, one
`or more severely stressful events, the disturbance is diag
`nosed as Brief Psychotic Disorder with Marked Stressor(s)
`(formerly labeled “brief reactive psychosis” in DSM-III-R).
`Brief Psychotic Disorder with Marked Stressor(s) is treatable
`by the glucocorticoid receptor antagonists of the present
`invention.
`Delirium is characterized by disturbances of consciousness
`and changes in cognition that develop over a relatively short
`period of time. The disturbance in consciousness is often
`manifested by a reduced clarity of awareness of the environ
`ment. The patient displays reduced ability to focus, Sustain or
`35
`shift attention (DSM-IV-TR diagnostic Criterion A). Accom
`panying the disturbance in consciousness, delirium patients
`display a disturbance in cognition (e.g., memory impairment,
`disorientation, language difficulties) or perceptual distur
`bances (e.g., misinterpretations, illusions, or hallucinations)
`(Criterion B). To be considered delirium, these disturbances
`in consciousness, cognition, or perception should develop
`over a short period of time and tend to fluctuate during the
`course of the day (Criterion C).
`Delirium may arise from a number of general medical
`conditions, including central nervous system disorders (e.g.,
`trauma, stroke, encephalopathies), metabolic disorders (e.g.,
`renal or hepatic insufficiency, fluid or electrolyte imbal
`ances), cardiopulmonary disorders (e.g., congestive heart
`failure, myocardial infarction, shock), and systemic illnesses
`or effects (e.g., infections, sensory deprivation, and postop
`erative states). Glucocorticoid receptor antagonists are also
`effective to treat Substance-Induced Delirium (e.g., delirium
`induced by Substance intoxication or withdrawal, medication
`side effects, and toxin exposure). Delirium may arise from
`multiple simultaneous etiologies (e.g., a combination of a
`general medical condition and Substance intoxication) and
`Such delirium, as well as delirium of unknown or unclassified
`origin, may be treated with the glucocorticoid receptor
`antagonists of the present invention.
`Mild cognitive impairment (MCI) is characterized as a
`mild impairment of cognition categorized as a CDR of 0.5
`that is associated with deficits in a memory task test, Such as
`a paragraph test. An MCI patient is fully oriented, but dem
`onstrates mild consistent forgetfulness. Impairment in cogni
`65
`tive domains other than memory, such as problem solving and
`judgment is doubtful, if present at all, and, further, the MCI
`
`55
`
`8
`patient does not demonstrate impairment in functioning in the
`community or at home. A patient with MCI scores normally
`on standard tests of dementia.
`There are various means to diagnose the onset of MCI and
`to assess the efficacy of treatment using the methods of the
`invention. These include the administration of psychiatric
`tests to determine the CDR, the administration of memory
`tests, and the administration of psychiatric tests for dementia,
`which are used to exclude a diagnosis of dementia. The results
`of these test may be considered in conjunction with other
`objective physical tests as described below. These means are
`also useful for assessing the efficacy of the methods of the
`invention in improving memory or decreasing or diminishing
`further impairment in memory or cognitive decline in a
`patient with MCI. Subjective and objective criteria can be
`used to measure and assess the Success of a particular GR
`antagonist, pharmaceutical formulation, dosage, treatment
`schedule or regimen. The features (symptoms) of and criteria
`for diagnosing MCI are described, e.g., in Petersen et al.,
`Arch. Neurol. 56:303-308, 1999.
`The dementia treated in the methods of the invention
`encompasses a broad range of mental conditions and Symp
`toms, as broadly described in the DSM-IV. While the practi
`tioner can use any set of prescribed or empirical criteria to
`diagnose the presence of dementia as an indication to practice
`the methods of the invention, Some illustrative diagnostic
`guidelines and examples of relevant symptoms and condi
`tions are described below.
`The DSM-IV states that dementias typically associated
`with Alzheimer's disease (dementia of the Alzheimer's type),
`“vascular dementia' (also known as multi-infarct dementia),
`or "dementia due to general medical conditions.” e.g., human
`immunodeficiency virus (HIV-1) disease, head trauma, Par
`kinson's disease, or Huntington's disease (further discussed,
`below). Dementias can also be “substance-induced persisting
`dementia, i.e., due to a drug of abuse, a medication, or toxin
`exposure, "dementia due to multiple etiologies, or a "demen
`tia not otherwise specified if the etiology is indeterminate.
`Psychosis can be manifested as a mental illness in the form
`of a syndrome or as an element of a variety of disease pro
`cesses. There are various means to diagnose these various
`forms of psychosis and assess the Success of treatment. These
`means include classical psychological evaluations in addition
`to the various laboratory procedures described above. Such
`means are well-described in the scientific and patent litera
`ture, and some illustrative examples are provided below.
`The psychosis ameliorated in the methods of the invention
`encompasses a broad range of mental conditions and Symp
`toms, as broadly described in the DSM-IV (Kaplan, ed.
`(1995) supra). Psychosis can refer to a symptom associated
`with a general medical condition, a disease state or other
`condition, such as a side effect of drug abuse (a Substance
`induced disorder) or as a side effect of a medication. While
`the practitioner can use any set of proscribed or empirical
`criteria to diagnose the presence of a psychosis as an indica
`tion to practice the methods of the invention, some illustrative
`diagnostic guidelines and examples of relevant symptoms
`and conditions are described below.
`Psychiatric conditions, such as psychosis, can be further
`diagnosed and evaluated using any of the many tests or crite
`ria well-known and

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket